LeadIQ logo
Learn more at LeadIQ.com

Insights

Strategic Acquisition ImmunoGen was recently acquired by AbbVie, a global biopharmaceutical company, in a $10.1 billion deal. This acquisition opens up opportunities for ImmunoGen to leverage AbbVie's global presence and resources, potentially leading to increased sales and market expansion.

Investment Influx Wealthminder, Inc. and SEB Group have made significant investments in ImmunoGen, totaling $815,000. This infusion of capital indicates investor confidence in ImmunoGen's technology and products, signaling potential growth and sales opportunities in the future.

Product Development ImmunoGen has launched a Phase 3 Study of Mirvetuximab Soravtansine in combination with Bevacizumab, targeting patients with recurrent platinum-sensitive cancers. This innovative approach and clinical trial could lead to the development of new therapies, creating sales opportunities in the oncology market.

Expansion through Partnerships Following its acquisition, ImmunoGen joined forces with AbbVie, focusing on creating impactful solutions in areas like immunology and oncology. By collaborating with a powerhouse like AbbVie, ImmunoGen can tap into new markets and channels, presenting lucrative sales possibilities.

Financial Stability With an annual revenue of $1 billion and a total funding of $62 million, ImmunoGen exhibits financial stability and growth potential. This financial strength can provide the foundation for scaling operations, investing in sales strategies, and capturing a larger market share.

ImmunoGen, Inc. Tech Stack

ImmunoGen, Inc. uses 8 technology products and services including SiteCatalyst, WordPress, AngularJS, and more. Explore ImmunoGen, Inc.'s tech stack below.

  • SiteCatalyst
    Analytics
  • WordPress
    Content Management System
  • AngularJS
    Javascript Frameworks
  • Underscore.js
    Javascript Libraries
  • jQuery Migrate
    Javascript Libraries
  • New Relic
    Real User Monitoring
  • Yoast SEO
    Search Engines
  • Bootstrap
    UI Frameworks

Media & News

ImmunoGen, Inc.'s Email Address Formats

ImmunoGen, Inc. uses at least 1 format(s):
ImmunoGen, Inc. Email FormatsExamplePercentage
first.last@immunogen.comJohn.Doe@immunogen.com
73%
flast@immunogen.comJDoe@immunogen.com
22%
last@immunogen.comDoe@immunogen.com
4%
last.first@immunogen.comDoe.John@immunogen.com
1%

Frequently Asked Questions

Where is ImmunoGen, Inc.'s headquarters located?

Minus sign iconPlus sign iconImmunoGen, Inc.'s main headquarters is located at 1 N Waukegan Rd North Chicago, Illinois 60064 US. The company has employees across 6 continents, including North AmericaEuropeAsia.

What is ImmunoGen, Inc.'s phone number?

Minus sign iconPlus sign icon You can contact ImmunoGen, Inc.'s main corporate office by phone at +1-781-895-0600. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is ImmunoGen, Inc.'s stock symbol?

Minus sign iconPlus sign iconImmunoGen, Inc. is a publicly traded company; the company's stock symbol is IMGN.

What is ImmunoGen, Inc.'s official website and social media links?

Minus sign iconPlus sign iconImmunoGen, Inc.'s official website is immunogen.com and has social profiles on LinkedIn.

How much revenue does ImmunoGen, Inc. generate?

Minus sign iconPlus sign icon As of July 2024, ImmunoGen, Inc.'s annual revenue reached $501B.

What is ImmunoGen, Inc.'s SIC code NAICS code?

Minus sign iconPlus sign iconImmunoGen, Inc.'s SIC code is 2834 - Pharmaceutical Preparations NAICS code is 3254 - Pharmaceutical and Medicine Manufacturing.

How many employees does ImmunoGen, Inc. have currently?

Minus sign iconPlus sign iconAs of July 2024, ImmunoGen, Inc. has approximately 355 employees across 6 continents, including North AmericaEuropeAsia. Key team members include Chief Financial Officer: L. W.Chief Medical Officer: J. O.Chief Financial Officer: H. A.. Explore ImmunoGen, Inc.'s employee directory with LeadIQ.

What industry does ImmunoGen, Inc. belong to?

Minus sign iconPlus sign iconImmunoGen, Inc. operates in the Pharmaceutical Manufacturing industry.

What technology does ImmunoGen, Inc. use?

Minus sign iconPlus sign iconImmunoGen, Inc.'s tech stack includes SiteCatalystWordPressAngularJSUnderscore.jsjQuery MigrateNew RelicYoast SEOBootstrap.

What is ImmunoGen, Inc.'s email format?

Minus sign iconPlus sign iconImmunoGen, Inc.'s email format typically follows the pattern of . Find more ImmunoGen, Inc. email formats with LeadIQ.

How much funding has ImmunoGen, Inc. raised to date?

Minus sign iconPlus sign icon As of July 2024, ImmunoGen, Inc. has raised $62M in funding. The last funding round occurred on May 09, 2023.
ImmunoGen, Inc.

ImmunoGen, Inc.

Pharmaceutical ManufacturingIllinois, United States10001+ Employees

ImmunoGen is now part of AbbVie.  

AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, eye care, aesthetics and other areas of unmet need.   

For more information about AbbVie, please visit us at www.abbvie.com. Follow AbbVie on LinkedIn for future updates.  

Review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.

Section iconCompany Overview

Headquarters
1 N Waukegan Rd North Chicago, Illinois 60064 US
Phone number
+1-781-895-0600
Website
immunogen.com
SIC Code
2834 - Pharmaceutical Preparations
Stock Symbol
IMGN
NAICS Code
3254 - Pharmaceutical and Medicine Manufacturing
Employees
10001+

Section iconMedia & News

Section iconFunding & Financials

  • $62M

    ImmunoGen, Inc. has raised a total of $62M of funding over 7 rounds. Their latest funding round was raised on May 09, 2023.

  • $1B

    ImmunoGen, Inc.'s revenue is in the range of $1B

Section iconFunding & Financials

  • $62M

    ImmunoGen, Inc. has raised a total of $62M of funding over 7 rounds. Their latest funding round was raised on May 09, 2023.

  • $1B

    ImmunoGen, Inc.'s revenue is in the range of $1B

Company Leadership

Employee Directory

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust LeadIQ to help them build pipeline confidently.

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.